Statement of Changes in Beneficial Ownership (4)
2023年4月6日 - 7:53AM
Edgar (US Regulatory)
FORM 4
☐
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
McRae Robert Curtis |
2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC.
[
PALI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer |
(Last)
(First)
(Middle)
7750 EL CAMINO REAL, SUITE 5200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/3/2023 |
(Street)
CARLSBAD,, CA 92009 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
(City)
(State)
(Zip)
|
Rule 10b5-1(c) Transaction Indication
☐
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to
satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, par value $0.01 (1) | 4/3/2023 | | M | | 655 (1) | A | $0.00 (1) | 895 | D | |
Common Stock, par value $0.01 (2) | 4/3/2023 | | F | | 270 | D | $2.00 (2) | 625 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Units (1) | (1) | 4/3/2023 | | M | | | 655 | (3) | (3) | Common Stock | 655 | (1) | 1963 | D | |
Explanation of Responses: |
(1) | Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
(2) | Represents shares withheld by Issuer to satisfy tax withholding requirements on vesting of restricted stock units. |
(3) | This restricted stock unit was granted on January 3, 2023, and 655 restricted stock units subject to the award vested on April 3, 2023, and approximately 654 restricted stock units are scheduled to vest on each of July 3, 2023, October 3, 2023, and January 3, 2023, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
McRae Robert Curtis 7750 EL CAMINO REAL, SUITE 5200 CARLSBAD,, CA 92009 |
|
| Chief Operating Officer |
|
Signatures
|
/s/ Robert McRae | | 4/5/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Seneca Biopharma (NASDAQ:SNCA)
過去 株価チャート
から 8 2024 まで 9 2024
Seneca Biopharma (NASDAQ:SNCA)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Seneca Biopharma Inc (ナスダック市場): 0 recent articles
その他のPalisade Bio, Inc.ニュース記事